The invention relates to a process for the preparation of a citrate-coated amorphous calcium phosphate nanoparticle which comprises the following steps: 1) providing a first solution of a salt of calcium and a citrate salt wherein the molar ratio of citrate ion to calcium ion is in the range from 1 to 2 thus obtaining a clear first solution; 2) providing a second solution of a salt capable to give phosphate anion and a carbonate salt; 3) mixing together the first and the second solution at a pH in the range from 8 to 11; 4) precipitating the nanoparticle; and 5) drying the nanoparticle obtained from step 4). Preferably and advantageously the invention provides for the addition of a fluoride compound in step 2) for obtaining a fluorine-doped citrate-coated calcium phosphate nanoparticle or a nanoparticle agglomerate. The nanoparticle/nanoparticle agglomerate of the invention has a peculiar superficial area and a diameter that allow to use it as a biomaterial for dentistry application.

The present disclosure features adhesive compositions and methods of use thereof related to the medical, veterinary, and dental fields.

The present disclosure features adhesive compositions and methods of use thereof related to the medical, veterinary, and dental fields.

The present invention relates to pharmaceutical compositions and methods for the treatment of peri-implant diseases, in particular peri-implant disease characterized by the destruction of the crest of the alveolar bone supporting the implant. Specifically, the method comprising the step of applying to a peri-implant bone displaying crestal resorption a 5 pharmaceutical composition comprising biocompatible bone augmentation material coated with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the bone loss site.

The present invention relates to pharmaceutical compositions and methods for the treatment of peri-implant diseases, in particular peri-implant disease characterized by the destruction of the crest of the alveolar bone supporting the implant. Specifically, the method comprising the step of applying to a peri-implant bone displaying crestal resorption a 5 pharmaceutical composition comprising biocompatible bone augmentation material coated with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the bone loss site.

A cosmetic and/or therapeutic treatment of tissue, such as tooth, is disclosed that effects, for instance, whitening and tissue re-building through mineralisation. Further, a method of performing iontophoresis utilizing an aqueous composition of a remineralising agent to achieve mineralisation is disclosed, as well as a kit for performing the mineralization or remineralisation.

The present invention provides a dentinal tubule occlusion material excellent in terms of initial degree of dentinal tubule occlusion, resistance of dentinal tubule occlusion to acids, handling properties, and storage stability. The present invention relates to an one-pack type dentinal tubule occlusion material comprising fluorapatite particles (A) having an average particle diameter of 0.6 to 10 m, inorganic particles (B) having an average particle diameter of 0.6 to 10 m and reactive with water to form apatite, and a non-aqueous dispersant (C).

Macroporous cement compositions, methods of making the same, and methods of using the same, are described.

A (e.g. hardenable dental) composition is described comprising (e.g. a first part comprising) an encapsulated material wherein the encapsulated material comprises a basic core material and an inorganic shell material comprising a metal oxide surrounding the core; and (e.g. a second part comprising) water or an acidic component. Also described is an encapsulated material (e.g. suitable for use in a biological carrier material) comprising a basic core material and an inorganic shell material comprising a metal oxide surrounding the core.

The present invention provides curable calcium phosphate dental cement that has excellent sealability for dentinal tubule, is expected to form fluoroapatite, and has a curing time that is advantageous for clinical use. The present invention is directed to curable calcium phosphate dental cement including: a first material as powder or nonaqueous paste; and a second material as liquid or aqueous paste, and, in the curable calcium phosphate dental cement, the first material comprises tetracalcium phosphate (A), alkali metal salt of phosphoric acid (B), and acidic calcium phosphate (C), the second material comprises water (D), and at least one of the first material and the second material comprises a fluorine compound (E) and an organic acid (F) having a molecular weight of 10000 or less.